Increasing use of non-statin and combination lipid-lowering therapies 2012–2025: a nationwide study

European Journal of Preventive Cardiology. 2025;  [DOI: 10.1093/eurjpc/zwaf720]. Epub Nov 12, 2025

Interessenskonflikte:

J.L.K. has received honoraria and/or travel grants from Boehringer Ingelheim, Daiichi Sankyo, Lilly, Novartis, and Synlab, outside of this work. U.L. has received speaker honoraria or consulting fees from Amgen, Apontis, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Daiichi Sankyo, Lilly, MSD, Novartis, NovoNordisk, Pfizer, Sanofi, and Synlab, outside of this work. M.S. has received speaker honoraria or consulting fees from Apontis, AstraZeneca, BMS, CSL Vifor, Daiichi Sankyo, Novartis, Pfizer, and TAD, outside of this work.